Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMC-P115C · 1 trial · 3 indications
Percentage of participants with dosing changes or discontinuations.
| Arm | Type | Description |
|---|---|---|
| Arm A: IMC-P115C Monotherapy | EXPERIMENTAL | Participants receive IMC-P115C intravenous (IV) infusion |
| Name | Type | Description |
|---|---|---|
| IMC-P115C | DRUG | IV infusion |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 * HLA-A\*02:01-positive * Meeting PRAME-positive tumor testing requirements * Metastatic or unresectable solid tumors * Have received (or be receiving), relapsed from, be refractory to or intolerant o...
IMC-P115C is an investigational small molecule being developed for the treatment of PRAME-positive cancers, including in patients who are HLA-A*02:01-positive. It is currently in Phase 1 clinical development for advanced PRAME-positive cancers.
IMC-P115C targets PRAME, a tumor-associated antigen. It is designed for cancers that express PRAME, and the clinical trial specifically enrolls patients who are HLA-A*02:01-positive, indicating the drug's mechanism involves PRAME-directed activity.
IMC-P115C is being developed by Immunocore Holdings plc, a biopharmaceutical company. The company's stock is listed under the ticker IMCR.
IMC-P115C is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing trial is recruiting patients with advanced PRAME-positive cancers.
IMC-P115C is being studied in a Phase 1 clinical trial with the identifier NCT07156136. This trial is titled 'Study of IMC-P115C in Advanced PRAME-Positive Cancers' and is currently recruiting participants in Australia, France, Italy, and Spain.